Consensus CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.7 ^USD	-2.86%		-2.86%	+9.68%

May. 28	Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	MT
May. 09	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	MT

Evolution of the average Target Price on CytomX Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a0a0e274b12bbcdcfae2a736.12cvxi26az5RWkGcZl-pXoHFGB2mR0iC9Gl0hKR7SFo.ug0C9WTYKnQOFhHTXgXfKbWxXWzPDzrQmCcMw5UScBvlAGyUaN8yURIIJg~7d4c4a450e4480fff542a92e9c05f026

Analyst Recommendations on CytomX Therapeutics, Inc.

Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	May. 28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	May. 09	MT
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	May. 09	MT
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8	May. 06	MT
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	Apr. 22	MT
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	Mar. 12	MT
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	Nov. 09	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.19 From $3.15, Keeps Market Perform Rating	23-08-09	MT
Mizuho Securities Adjusts CytomX Therapeutics Price Target to $2 From $4, Maintains Neutral Rating	23-03-28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.20 From $2.60, Maintains Market Perform Rating	23-01-06	MT
BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3	22-11-14	MT
JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight	22-11-10	MT
Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform	22-07-11	MT
HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy	22-07-11	MT
Jefferies Downgrades CytomX Therapeutics to Hold From Buy, Lowers Price Target to $2 From $12	22-07-07	MT
Piper Sandler Downgrades CytomX Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.50 From $10	22-07-07	MT
BTIG Lowers CytomX Therapeutics' Price Target to $8 From $16, Buy Rating Kept	22-07-07	MT
BMO Capital Lowers CytomX Therapeutics' Price Target to $3 From $9, Outperform Rating Maintained	22-07-07	MT
Barclays Adjusts CytomX Therapeutics' Price Target to $3.50 From $7, Keeps Overweight Rating	22-07-07	MT
Wedbush Cuts CytomX Therapeutics to Neutral From Outperform, Price Target to $2 From $6, Citing Praluzatamab Ravtansine Update, 'Tough Financing Environment'	22-07-07	MT
Piper Sandler Cuts CytomX Therapeutics to Neutral From Overweight, Price Target to $1.50 From $10	22-07-07	MT
Mizuho Securities Cuts CytomX Therapeutics to Neutral From Buy, Price Target to $4 From $16	22-07-07	MT
BMO Capital Starts CytomX Therapeutics at Outperform With $9 Price Target	22-06-24	MT
Piper Sandler Adjusts Price Target on CytomX Therapeutics to $10 From $16, Reiterates Overweight Rating	22-05-31	MT
Wedbush Adjusts Price Target for CytomX Therapeutics to $6 From $10, Maintains Outperform Rating	22-05-10	MT